The Insider: Meet the CEOs Webcast Replay
We were joined by the CEOs of ASX-listed businesses, who gave valuable insight to their industries and companies future prospects.
- (ASX: PTX) Prescient Therapeutics Limited- Steven Yatomi-Clarke
- (ASX: ACF) Acrow Formwork and Construction Services Ltd – Steve Boland
Recorded on 19th April 2023 at 12pm (AEST).
FEATURED SPEAKERS
Steven Yatomi-Clarke
CEO and Managing Director - Prescient Therapeutics (ASX: PTX)
Prescient Therapeutics is a clinical-stage oncology company focused on developing next-generation personalised cancer therapies within the total global US$280 billion (2021) oncology industry. The company has collaborated with world-leading cancer institutions such as Peter MacCallum Cancer Centre and the largest cancer centre in the US, MD Anderson. As at March 2023, Prescient’s PTX-100 targeted cancer therapy was demonstrating encouraging clinical trial results, including the complete eradication of cancer with an excellent safety profile exceeding the standard of care. The company also owns a next-generation OmniCAR cell therapy that is capable of reshaping cancer treatment by making existing cancer therapies safer, cheaper and more effective.
Steve Boland
CEO - Acrow Formwork and Construction Services Ltd (ASX: ACF)
Acrow provides smart integrated construction systems and in-house engineering, safety and project management solutions to Australia’s civil infrastructure, industrial and commercial construction sectors. The company’s portfolio includes the redevelopment of projects such as Melbourne Cricket Ground, Kogan Creek Power Station, the Brisbane Airport Link and AAMI Park (Melbourne). Following a record breaking H1 FY23 and a slew of major project wins, the company plans to broaden its footprint across Australia’s civil infrastructure market, with a focus on New South Wales and Victoria. The company has secured packages in Sydney’s Gateway and M12 Motorway and Victoria’s West Gate Tunnel and Cross Yarra Partnership (Metro Tunnel) projects with revenues expected in March-April 2023.
Past performance is not a reliable indicator of future performance.
Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
